GSK has announced positive results from a second Phase III trial of Blenrep in relapsed/refractory multiple myeloma, making its return to the market increasingly likely.
The drug was removed from the US market in 2022 at the request of the US Food and Drug Administration,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?